Rubén Pı́o

8.4k total citations · 1 hit paper
132 papers, 5.7k citations indexed

About

Rubén Pı́o is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Rubén Pı́o has authored 132 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 41 papers in Pulmonary and Respiratory Medicine and 40 papers in Immunology. Recurrent topics in Rubén Pı́o's work include Complement system in diseases (29 papers), Lung Cancer Treatments and Mutations (26 papers) and Lung Cancer Diagnosis and Treatment (20 papers). Rubén Pı́o is often cited by papers focused on Complement system in diseases (29 papers), Lung Cancer Treatments and Mutations (26 papers) and Lung Cancer Diagnosis and Treatment (20 papers). Rubén Pı́o collaborates with scholars based in Spain, United States and United Kingdom. Rubén Pı́o's co-authors include Luis M. Montuenga, Daniel Ajona, María J. Pajares, John D. Lambris, Leticia Corrales, Frank Cuttitta, Alfredo Martı́nez, Jackeline Agorreta, Sergio Ortiz‐Espinosa and Javier J. Zulueta and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Rubén Pı́o

125 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

2018 357 citations Luis Seijó, Daniel Ajona et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rubén Pı́o Spain	44	2.8k	1.6k	1.3k	1.2k	1.1k	132	5.7k
Yasuhiro Hida Japan	42	3.0k 1.1×	910 0.6×	1.7k 1.3×	815 0.7×	1.8k 1.7×	162	5.5k
Jiro Fujimoto Japan	39	3.6k 1.3×	1.2k 0.7×	1.5k 1.1×	694 0.6×	898 0.8×	234	7.4k
Sophia Ran United States	35	3.1k 1.1×	2.5k 1.5×	2.7k 2.0×	609 0.5×	1.0k 1.0×	74	6.6k
Diane R. Bielenberg United States	40	3.1k 1.1×	737 0.5×	1.9k 1.4×	503 0.4×	1.1k 1.0×	95	5.5k
Anna‐Karin Olsson Sweden	28	2.7k 0.9×	1.2k 0.7×	1.1k 0.9×	438 0.4×	848 0.8×	65	4.8k
Kiyosumi Shibata Japan	41	2.1k 0.7×	1.0k 0.6×	2.2k 1.6×	608 0.5×	994 0.9×	195	5.9k
József Tı́már Hungary	50	4.0k 1.4×	1.3k 0.8×	3.2k 2.4×	1.4k 1.1×	1.9k 1.8×	328	8.4k
Yoshiro Maru Japan	35	3.3k 1.2×	1.2k 0.8×	1.5k 1.1×	414 0.3×	900 0.8×	89	5.4k
Pierre‐Yves Dietrich Switzerland	47	2.5k 0.9×	3.3k 2.0×	2.7k 2.0×	892 0.7×	981 0.9×	174	7.4k
Qiang Wang China	40	3.0k 1.0×	864 0.5×	1.4k 1.1×	523 0.4×	814 0.8×	191	5.3k

Countries citing papers authored by Rubén Pı́o

Since Specialization

Citations

This map shows the geographic impact of Rubén Pı́o's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rubén Pı́o with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rubén Pı́o more than expected).

Fields of papers citing papers by Rubén Pı́o

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rubén Pı́o. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rubén Pı́o. The network helps show where Rubén Pı́o may publish in the future.

Co-authorship network of co-authors of Rubén Pı́o

This figure shows the co-authorship network connecting the top 25 collaborators of Rubén Pı́o. A scholar is included among the top collaborators of Rubén Pı́o based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rubén Pı́o. Rubén Pı́o is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ajona, Daniel, et al.. (2025). Opposing effects of animal models of type 1 and type 2 diabetes on factor D expression and systemic alternative pathway activity. Immunobiology. 230(4). 153077–153077.

Pı́o, Rubén, Yaiza Senent, Beatriz Tavira, & Daniel Ajona. (2024). Fasting and fasting-mimicking conditions in the cancer immunotherapy era. Journal of Physiology and Biochemistry. 81(2). 383–389. 3 indexed citations

Senent, Yaiza, Ana Remírez, Diana Llópiz, et al.. (2024). The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response. Cancer Immunology Research. 13(3). 384–399. 6 indexed citations

Ajona, Daniel, Mark S. Cragg, & Rubén Pı́o. (2024). The complement system in clinical oncology: Applications, limitations and challenges. Seminars in Immunology. 77. 101921–101921. 12 indexed citations

Morales, Xabier, Sergio Ortiz‐Espinosa, Borja Ruiz‐Fernández de Córdoba, et al.. (2022). Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood. Bioengineering & Translational Medicine. 7(3). e10331–e10331. 7 indexed citations

Senent, Yaiza, Beatriz Tavira, Susana Inogés, et al.. (2022). C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d. Frontiers in Immunology. 13. 946522–946522. 5 indexed citations

Martínez‐Terroba, Elena, Teresa Ezponda, Cristina Bértolo, et al.. (2018). The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer. Laboratory Investigation. 98(12). 1562–1574. 31 indexed citations

Ajona, Daniel, Carolina Zandueta, Leticia Corrales, et al.. (2018). Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. American Journal of Respiratory and Critical Care Medicine. 197(9). 1164–1176. 72 indexed citations

Ajona, Daniel, Sergio Ortiz‐Espinosa, Haritz Moreno, et al.. (2017). A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. Cancer Discovery. 7(7). 694–703. 187 indexed citations

10.

Ajona, Daniel, et al.. (2017). MA09.01 Dual Blockade of PD-1 and C5a/C5aR Synergistically Protects against Non-Small Cell Lung Cancer Tumor Growth. Journal of Thoracic Oncology. 12(1). S391–S391. 1 indexed citations

11.

Díaz‐Lagares, Ángel, Jesús Méndez‐González, David Hervás, et al.. (2016). A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer. Clinical Cancer Research. 22(13). 3361–3371. 103 indexed citations

12.

Sánchez-Salcedo, Pablo, David O. Wilson, Juan P. de‐Torres, et al.. (2015). Improving Selection Criteria for Lung Cancer Screening. The Potential Role of Emphysema. American Journal of Respiratory and Critical Care Medicine. 191(8). 924–931. 67 indexed citations

13.

Agorreta, Jackeline, Domenico Delia, Helen Turley, et al.. (2014). TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC. Molecular Cancer Research. 12(5). 660–669. 63 indexed citations

14.

Miguel, Fernando J. de, Ravi Datta Sharma, María J. Pajares, et al.. (2013). Identification of Alternative Splicing Events Regulated by the Oncogenic Factor SRSF1 in Lung Cancer. Cancer Research. 74(4). 1105–1115. 68 indexed citations

15.

Ponz‐Sarvisé, Mariano, Paul Nguewa, Jackeline Agorreta, et al.. (2011). Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance. Clinical Cancer Research. 17(12). 4155–4166. 40 indexed citations

16.

Ezponda, Teresa, María J. Pajares, Jackeline Agorreta, et al.. (2010). The Oncoprotein SF2/ASF Promotes Non–Small Cell Lung Cancer Survival by Enhancing Survivin Expression. Clinical Cancer Research. 16(16). 4113–4125. 46 indexed citations

17.

Pı́o, Rubén, Leticia Corrales, Daniel Ajona, et al.. (2010). Complement Factor H Is Elevated in Bronchoalveolar Lavage Fluid and Sputum from Patients with Lung Cancer. Cancer Epidemiology Biomarkers & Prevention. 19(10). 2665–2672. 27 indexed citations

18.

Zudaire, Isabel, Rubén Pı́o, José I. Martı́n-Subero, et al.. (2009). FICTION as a new tool to early lung cancer diagnosis. Anales del Sistema Sanitario de Navarra. 25(3). 305–315.

19.

Ajona, Daniel, et al.. (2007). Down-Regulation of Human Complement Factor H Sensitizes Non-Small Cell Lung Cancer Cells to Complement Attack and Reduces In Vivo Tumor Growth. The Journal of Immunology. 178(9). 5991–5998. 86 indexed citations

20.

Pı́o, Rubén, et al.. (1998). Granule associated DNase in T4 and T8 lymphocytes from patients with autoimmune diseases. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1406(1). 51–61. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact